AR054191A1 - Compuestos de 3 aminopirrolidina sustituidos utiles como inhibidores de la recaptacion de monoamina - Google Patents

Compuestos de 3 aminopirrolidina sustituidos utiles como inhibidores de la recaptacion de monoamina

Info

Publication number
AR054191A1
AR054191A1 ARP060101917A ARP060101917A AR054191A1 AR 054191 A1 AR054191 A1 AR 054191A1 AR P060101917 A ARP060101917 A AR P060101917A AR P060101917 A ARP060101917 A AR P060101917A AR 054191 A1 AR054191 A1 AR 054191A1
Authority
AR
Argentina
Prior art keywords
group
lower alkyl
groups
substituted
optionally substituted
Prior art date
Application number
ARP060101917A
Other languages
English (en)
Inventor
Nobuaki Ito
Kuninori Tai
Noriaki Takemura
Yasuhiro Menjo
Shin Miyamura
Yohji Sakurai
Yasuyo Sakata
Takumi Masumoto
Kohei Akazawa
Naoki Amada
Satoshi Ohashi
Tomoichi Shinohara
Hirofumi Sasaki
Junko Yamashita
Satoko Nakajima
Muneaki Kurimura
Shinichi Taira
Haruhiko Sugino
Takahiro Tomoyasu
Takayuki Matsuzaki
Akihito Watanabe
Chisako Morita
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36693623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054191(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR054191A1 publication Critical patent/AR054191A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

El compuesto de pirrolidina o una sal del mismo de la presente puede usarse para producir una preparacion farmacéutica de espectro terapéutico más amplio y capaz de exhibir suficientes efectos terapéuticos luego de un corto término de administracion. Reivindicacion 1: Un compuesto de pirrolidina de formula general (1), o una sal del mismo, caracterizado porque cada uno de R101 y R102 es independientemente uno de los siguientes grupos (1) a (86): (1) un grupo fenilo , (2) un grupo piridilo; (3) a un grupo benzotienilo; (4) un grupo indolilo; (5) un grupo 2, 3-dihidro-lH-indenilo; (6) un grupo naftilo; (7) un grupo benzofurilo; (8) un grupo quinolilo;(9) un grupo tiazolilo; (10) un grupo pirimidinilo; (11) un grupo pirazinilo; (12) un grupo benzotiazolilo; (13) un grupo tieno[3, 2-b]piridilo; (14) un grupo tienilo; (15) un grupo cicloalquilo; (16) un grupo tetrahidropiranilo; (17) un grupo pirrolilo; (18) un grupo 2, 4-dihidro-l, 3-benzodioxinilo; (19) un grupo 2, 3-dihidrobenzofurilo; (20) un grupo 9H-fluorenilo; (21) un grupo pirazolilo; (22) un grupo piridazinilo; (23) un grupo indolinilo; (24) un grupo tieno[2, 3-b]piridilo; (25) un grupo tieno[3, 2-d]pirimidinio; (26) un grupo tieno [3, 2- e]pirimidinilo; (27) un grupo lH-pirazolo[3, 4-b]piridilo; (28) un grupo isoquinolilo; (29) un grupo 2,3-dihidro-l,4-benzoxadinilo; (30) un grupo quinoxalinilo; (31) un grupo quinazolinilo; (32) un grupo 1,2,3,4-tetrahidroquinolilo; (33) un grupo cicloalquilo alquilo inferior; (34) un grupo alquilo inferior alquiltio inferior; (35) un grupo alquilo inferior amino-sustituido opcionalmente sustituido por uno o dos grupos alquilo inferior en el grupo amino; (36) un grupo fenoxi alquilo inferior; (37) un grupo piridiloxi alquilo inferior; (38) un grupo alquinilo inferior; (39) un grupo fenilo alquenilo inferior; (40) un grupo 1, 3-benzodioxolilo; (41) un grupo 2,3-dihidro-l, -benzodioxinilo; (42) un grupo 3,4-dihidro-l,5- benzodioxepinilo; (43) un grupo dihidropiridilo; (44) un grupo 1, 2-dihidroquinolilo; (45) un grupo 1,2,3,4-tetrahidroisoquinolilo; (46) un grupo benzoxazolilo; (47) un grupo benzoisotiazolilo; (48) un grupo indazolilo; (49) un grupo benzoimidazolilo; (50) un grupo imidazolilo; (51) un grupo 1,2,3,4-tetrahidronaftilo alquilo inferior; (52) un grupo imidazo[1,2-a]piridilo alquilo inferior; (53) un grupo tiazolilo alquilo inferior; (54) un grupo tetrahidropiranilo alquilo inferior; (55) un grupo piperidilo alquilo inferior; (56) un grupo difenilo alcoxi inferior-sustituido alquilo inferior; (57) un grupo alcoxicarbonilo inferior-sustituido alquilo inferior; (58) un grupo fenilo alcoxicarbonilo inferior-sustituido alquilo inferior; (59) un grupo hidroxi-sustituido alquilo inferior; (60) un grupo alcoxi inferior alquilo inferior; (61) un grupo carboxi alquilo inferior; (62) un grupo carbamoilo-sustituido alquilo inferior opcionalmente sustituido con uno o dos grupos alquilo inferior en el grupo carbamoilo; (63) un grupo alquenilo inferior; (64) un grupo morfolinilocarbonilo alquilo inferior; (65) un grupo benzoílo alquilo inferior; (66) un grupo feniltio alquilo inferior; (67) un grupo naftiltio alquilo inferior; (68) un grupo cicloalquiltio alquilo inferior; (69) un grupo piridiltio alquilo inferior; (70) un grupo pirimidiniltio alquilo inferior; (71) un grupo furiltio alquilo inferior; (72) un grupo tieniltio alquilo inferior; (73) un grupo 1,3,4- tiadiazoliltio alquilo inferior; (74) un grupo benzimidazoliltio alquilo inferior; (75) un grupo benzotiazoliltio alquilo inferior; (76) un grupo tetrazoliltio alquilo inferior; (77) un grupo benzoxazoliltio alquilo inferior; (78) un grupo tiazoliltio alquilo inferior; (79) un grupo imidazoliltio alquilo inferior; (80) un grupo amino-sustituido alquilo inferior alquiltio inferior opcionalmente sustituido con uno o dos grupos alquilo inferior en el grupo amino; (81) un grupo fenilo- sustituido alquilo inferior alquiltio inferior; (82) un grupo furilo-sustituido alquilo inferior alquiltio inferior; (83) un grupo piridilo-sustituido alquilo inferior alquiltio inferior; (84) un grupo hidroxi-sustituido alquilo inferior alquiltio inferior; (85) un grupo fenoxi-sustituido alquilo inferior alquiltio inferior; y (86) un grupo alcoxicarbonilo inferior-sustituido alquilo inferior alquiltio inferior; y cada uno de los grupos (1) a (32), (37), (39) a (56), (64) a (79), (81) a (83) y (85) pueden tener uno o más sustituyentes seleccionados entre los siguientes (1-1) a (1-37) en el anillo cicloalquilo, aromático o heterocíclico; (1-1) átomos de halogeno; (1-2) grupos alquiltio inferior opcionalmente sustituidos con uno o más átomos de halogeno; (1-3) grupos alquilo inferior opcionalmente sustituidos con uno o más átomos de halogeno; (1-4) grupos alcoxi inferior opcionalmente sustituidos con uno o más átomos de halogeno; (1-5) un grupo nitro; (1-6) grupos alcoxi inferior carbonilo; (1-7) grupos amino opcionalmente sustituidos con uno o dos grupos alquilo inferior; (1-8) grupos alquilo inferior sulfonilo; (1-9) un grupo ciano; (1-10) un grupo carboxi; (1-11) un grupo hidroxi; (1-12) grupos tienilo; (1-13) grupos oxazolilo; (1-14) grupos naftilo; (1-15) un grupo benzoílo; (1-16) grupos fenoxi opcionalmente sustituidos con uno a tres átomos de halogeno en el anillo fenilo; (1-17) grupos fenilo alcoxi inferior; (1-18) grupos alcanoilo inferior; (1-19) grupos fenilo opcionalmente sustituidos en el anillo fenilo con uno a cinco sustituyentes seleccionados dentro del grupo consistente en átomos de halogeno, grupos alcoxi inferior, un grupo ciano, grupos alcanoilo inferior y grupos alquilo inferior; (1-20) grupos fenilo alquilo inferior; (1-21) grupos ciano alquilo inferior; (1-22) grupos de 5 a 7 miembros saturados sulfonilo sustituido por un grupo heterocíclico, el grupo heterocíclico contiene en el anillo heterocíclico uno o dos heteroátomos seleccionados dentro del grupo consistente en nitrogeno, oxígeno y azufre; (1-23) grupos tiazolilo opcionalmente sustituidos con uno o dos grupos alquilo inferior en el anillo tiazol; (1-24) grupos imidazolilo; (1-25) grupos amino alquilo inferior opcionalmente sustituidos con uno o dos grupos alquilo inferior en el grupo amino; (1-26) grupos pirrolidinilo alcoxi inferior; (1-27) grupos isoxazolilo; (1-28) grupos cicloalquilocarbonilo; (1-29) grupos naftiloxi; (1-30) grupos piridilo; (1-31) grupos furilo; (1-32) grupos feniltio; (1-33) grupo oxo; (1-34) grupo carbamoilo; (1-35) grupos heterocíclico saturados de 5 a 7 miembros que contienen uno o dos heteroátomos seleccionados dentro del grupo consistente en nitrogeno, oxígeno y azufre, estando el grupo heterocíclico opcionalmente sustituido por uno a tres sustituyentes seleccionados dentro del grupo consistente en el grupo oxo; grupos alquilo inferior; grupos alcanoilo inferior; grupos fenilo alquilo inferior; grupos fenilo opcionalmente sustituidos en el anillo fenilo por uno a tres miembros seleccionados dentro del grupos consistente en átomos de halogeno y grupos alcoxi inferior; y grupos piridilo; (1-36) grupo oxido; y (1-37) grupos alcoxido inferior; siempre que R101 y R102 no sean simultáneamente fenilo insustituido.
ARP060101917A 2005-05-13 2006-05-12 Compuestos de 3 aminopirrolidina sustituidos utiles como inhibidores de la recaptacion de monoamina AR054191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005141230 2005-05-13

Publications (1)

Publication Number Publication Date
AR054191A1 true AR054191A1 (es) 2007-06-06

Family

ID=36693623

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101917A AR054191A1 (es) 2005-05-13 2006-05-12 Compuestos de 3 aminopirrolidina sustituidos utiles como inhibidores de la recaptacion de monoamina

Country Status (25)

Country Link
US (6) US8084442B2 (es)
EP (2) EP1881975B8 (es)
JP (1) JP4776631B2 (es)
KR (2) KR20100038453A (es)
CN (3) CN103613587A (es)
AR (1) AR054191A1 (es)
AU (2) AU2006244851B2 (es)
BR (1) BRPI0610279A2 (es)
CA (1) CA2608184C (es)
CY (1) CY1114767T1 (es)
DK (1) DK2407451T3 (es)
ES (2) ES2451523T3 (es)
HK (1) HK1193094A1 (es)
IL (1) IL187311A (es)
IN (1) IN2012DN00758A (es)
MX (1) MX2007014252A (es)
MY (1) MY148653A (es)
PL (1) PL2407451T3 (es)
PT (1) PT2407451E (es)
RU (1) RU2414454C2 (es)
SG (1) SG162722A1 (es)
SI (1) SI2407451T1 (es)
TW (3) TWI410406B (es)
WO (1) WO2006121218A1 (es)
ZA (1) ZA200709691B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE555087T1 (de) 2002-11-27 2012-05-15 Incyte Corp 3-aminopyrrolidinderivate als modulatoren von chemokinrezeptoren
TWI410406B (zh) * 2005-05-13 2013-10-01 Otsuka Pharma Co Ltd 吡咯烷化合物
EP1960355A1 (en) * 2005-11-30 2008-08-27 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles and aza-substituted indoles
JP2009518313A (ja) * 2005-11-30 2009-05-07 スミスクライン・ビーチャム・コーポレイション ピロリジンアニリン
JP5219465B2 (ja) * 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
AU2009226868A1 (en) * 2008-03-20 2009-09-24 F. Hoffmann-La Roche Ag Pyrrolidinyl derivatives and uses thereof
AU2010314518B2 (en) * 2009-11-07 2016-04-21 Merck Patent Gmbh Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors
US8541596B2 (en) * 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
CN102766079B (zh) * 2011-05-06 2015-04-08 上海医药工业研究院 一类吡咯烷衍生物、其制备方法及应用
EP3052190A4 (en) 2013-10-01 2017-07-19 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
KR20160148871A (ko) 2015-06-17 2016-12-27 양순구 일방향 클러치 제동장치
WO2017070796A1 (en) * 2015-10-30 2017-05-04 Trillium Therapeutics Inc. Heterocycle derivatives and their use for the treatment of cns disorders
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
RU2698400C1 (ru) * 2018-12-17 2019-08-26 Георгий Сергеевич Немов Способ лечения депрессии у собак и кошек
CN113024517A (zh) * 2019-12-09 2021-06-25 武汉九州钰民医药科技有限公司 一种制备厄达替尼的方法
CN113024518A (zh) * 2019-12-09 2021-06-25 武汉九州钰民医药科技有限公司 一种厄达替尼的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1164828A (en) 1965-10-23 1969-09-24 Robins Co Inc A H 3-(2-Substituted Ethyl)Indoles and their Manufacture and Use
GB1173373A (en) 1966-03-22 1969-12-10 Robins Co Inc A H Substituted 3-Aminopyrrolidines
US3509171A (en) * 1967-09-14 1970-04-28 Robins Co Inc A H 3-amino-1-carbamyl and thiocarbamyl pyrrolidines
US3433802A (en) * 1968-06-25 1969-03-18 Robins Co Inc A H 3-(n-lower-alkylanilino)pyrrolidines
US3577440A (en) * 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-amido-pyrrolidines
GB1523631A (en) 1975-07-08 1978-09-06 Leo Pharm Prod Ltd Sulphonamide derivatives
US4254135A (en) * 1979-10-16 1981-03-03 A. H. Robins Company, Inc. 3-Amino-4-hydroxypyrrolidines
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
SE9604786D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
EP1138672A1 (en) 1998-01-12 2001-10-04 Basilea Pharmaceutica AG Process for the preparation of 3-amino-pyrrolidine derivatives
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
WO2001083434A2 (en) * 2000-04-28 2001-11-08 F. Hoffmann-La Roche Ag P-(sulfonyl)-aryl and heteroaryls amines
IL158631A0 (en) 2001-05-18 2004-05-12 Astrazeneca Ab 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
EP1638934B1 (en) * 2003-06-11 2008-01-09 Eli Lilly And Company 3-aminopyrrolidines as inhibitors of monoamine uptake
AP2005003467A0 (en) * 2003-06-17 2006-12-31 Pfizer N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline reuptake inhibitors.
GB0314054D0 (en) 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US7432280B2 (en) 2003-06-20 2008-10-07 Eli Lilly And Company 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake
US7989634B2 (en) 2003-11-12 2011-08-02 Lg Life Sciences Ltd. Melanocortin receptor agonists
JP2007513945A (ja) * 2003-12-12 2007-05-31 イーライ リリー アンド カンパニー 体熱感、衝動調節障害および一般的な病状による人格変化の治療
JP2008536950A (ja) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
TWI410406B (zh) * 2005-05-13 2013-10-01 Otsuka Pharma Co Ltd 吡咯烷化合物
EP2035763A1 (en) * 2006-06-30 2009-03-18 Arcelik Anonim Sirketi A cooling device

Also Published As

Publication number Publication date
US20180258038A1 (en) 2018-09-13
EP2407451A1 (en) 2012-01-18
IL187311A0 (en) 2008-04-13
ES2451523T3 (es) 2014-03-27
BRPI0610279A2 (pt) 2010-06-08
CA2608184C (en) 2013-09-24
MX2007014252A (es) 2008-01-22
US9611214B2 (en) 2017-04-04
JP4776631B2 (ja) 2011-09-21
PL2407451T3 (pl) 2014-04-30
EP1881975B1 (en) 2014-01-08
RU2010128620A (ru) 2012-01-20
ES2451523T8 (es) 2014-06-20
RU2414454C2 (ru) 2011-03-20
US10000450B2 (en) 2018-06-19
EP1881975B8 (en) 2014-04-09
IN2012DN00758A (es) 2015-06-19
KR100971850B1 (ko) 2010-07-22
US8420623B2 (en) 2013-04-16
CN103613527A (zh) 2014-03-05
WO2006121218A1 (en) 2006-11-16
HK1193094A1 (zh) 2014-09-12
EP2407451B1 (en) 2013-11-20
PT2407451E (pt) 2014-01-13
CY1114767T1 (el) 2016-12-14
TWI410406B (zh) 2013-10-01
TW201319037A (zh) 2013-05-16
TWI449692B (zh) 2014-08-21
US8815871B2 (en) 2014-08-26
ZA200709691B (en) 2009-09-30
ES2446375T3 (es) 2014-03-07
US20130203750A1 (en) 2013-08-08
DK2407451T3 (da) 2013-12-16
US20170166524A1 (en) 2017-06-15
JP2008540329A (ja) 2008-11-20
EP1881975A1 (en) 2008-01-30
TWI439452B (zh) 2014-06-01
US20090088406A1 (en) 2009-04-02
MY148653A (en) 2013-05-15
CA2608184A1 (en) 2006-11-16
TW200720249A (en) 2007-06-01
AU2006244851B2 (en) 2010-06-10
AU2006244851A1 (en) 2006-11-16
KR20100038453A (ko) 2010-04-14
CN103613527B (zh) 2016-02-24
RU2007146512A (ru) 2009-06-20
US8084442B2 (en) 2011-12-27
CN101175748A (zh) 2008-05-07
CN103613587A (zh) 2014-03-05
TW201412708A (zh) 2014-04-01
AU2010201952A1 (en) 2010-06-10
IL187311A (en) 2012-08-30
KR20080008423A (ko) 2008-01-23
US20140288065A1 (en) 2014-09-25
US20120065162A1 (en) 2012-03-15
SI2407451T1 (sl) 2014-02-28
SG162722A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
AR054191A1 (es) Compuestos de 3 aminopirrolidina sustituidos utiles como inhibidores de la recaptacion de monoamina
ES2778700T3 (es) Nuevos derivados de piperidinilo sustituidos con (hetero)arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
AU2021201244B2 (en) Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
JP6609258B2 (ja) ヘテロアリール及びそれらの使用
WO2019099926A1 (en) Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
ES2712875T3 (es) Compuestos heterocíclicos útiles como inhibidores de PDK1
RU2503676C2 (ru) Пирролопиразиновые ингибиторы киназы
EP3774789A1 (en) Brm targeting compounds and associated methods of use
BR112019012993A2 (pt) derivados de benzo-oxazol como imunomoduladores
JP2021523221A (ja) Ｐｔｐｎ１１の置換されたヘテロ環式インヒビター
CA2939164A1 (en) Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
AR074902A1 (es) Derivados de 1,2,4-oxadiazoles agonistas de receptores s1p1
AU2016203414A1 (en) Compounds useful as inhibitors of ATR kinase
HRP20110428T1 (hr) Derivati piperidin-amino-benzimidazola kao inhibitori respiratorne sincitijalne virusne replikacije
PE20081612A1 (es) Analogos de las pterinas
RU2007107910A (ru) Гетероциклические соединения
ES2860299T3 (es) Inhibidores de DNA-PK
PE20121126A1 (es) Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
PE20090596A1 (es) Imidazoles biciclicos fusionados
RU2007133655A (ru) Замещенные бис-арильные и гетероарильные соединения в качестве селективных антагонистов 5нт2а
WO2022047145A1 (en) Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
KR101552361B1 (ko) 신규 이미다졸론 유도체, 이들의 약물, 제약 조성물로서의 제법, 및 이들의 단백질 키나제 억제제, 특히 ｃｄｃ７ 억제제로서의 용도
KR20190020343A (ko) 벤조디옥산 유도체 및 이의 약제학적 용도
JP2019502680A5 (es)
EP3170822A1 (en) Azaindole derivatives and their use as erk kinase inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure